CA Patent

CA2764475A1 — Crystalline form of 2-{4[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide

Assigned to Nippon Shinyaku Co Ltd · Expires 2010-12-29 · 15y expired

What this patent protects

Provided are the following novel crystals of 2-{4-[N-(5,6-diphenylpyradin-2-yl)-N-isopropylamino]butyl­oxy}-N-(methylsulfonyl)acetamide (hereinafter, referred to as "compound A"): I-form crystals of the compound A which give an X-ray powder diffraction spectrum having dif…

USPTO Abstract

Provided are the following novel crystals of 2-{4-[N-(5,6-diphenylpyradin-2-yl)-N-isopropylamino]butyl­oxy}-N-(methylsulfonyl)acetamide (hereinafter, referred to as "compound A"): I-form crystals of the compound A which give an X-ray powder diffraction spectrum having diffraction peaks at least at diffraction angles (2?) of 9.4º, 9.8º, 17.2º, and 19.4º; II-form crystals of the compound A which give an X-ray powder diffraction spectrum having diffraction peaks at least at diffraction angles (2?) of 9.0º, 12.9º, 20.7º, and 22.6º; and III-form crystals of the compound A which give an X-ray powder diffraction spectrum having diffraction peaks at least at diffraction angles (2?) of 9.3º, 9.7º, 16.8º, 20.6º, and 23.5º.

Drugs covered by this patent

Patent Metadata

Patent number
CA2764475A1
Jurisdiction
CA
Classification
—
Expires
2010-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Nippon Shinyaku Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.